[go: up one dir, main page]

AR059037A1 - Compuestos para el tratamiento de trastornos inflamatorios - Google Patents

Compuestos para el tratamiento de trastornos inflamatorios

Info

Publication number
AR059037A1
AR059037A1 ARP070100164A ARP070100164A AR059037A1 AR 059037 A1 AR059037 A1 AR 059037A1 AR P070100164 A ARP070100164 A AR P070100164A AR P070100164 A ARP070100164 A AR P070100164A AR 059037 A1 AR059037 A1 AR 059037A1
Authority
AR
Argentina
Prior art keywords
aryl
heteroaryl
heterocyclyl
alkyl
cycloalkyl
Prior art date
Application number
ARP070100164A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38038495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR059037(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of AR059037A1 publication Critical patent/AR059037A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Estos compuestos pueden ser utiles para el tratamiento de enfermedades o afecciones mediadas por las MMP, ADAM, TACE, agrecanasa, TNF-a o combinaciones de las mismas. Reivindicacion 1: Un compuesto representado por la formula (1), o una de sus sales, solvatos, o ésteres aceptables para uso farmacéutico, donde: el anillo A se selecciona del grupo que consiste en arilo y heteroarilo, estando cada uno ellos substituido con -Y-R1 y -Z-R2 como se muestra; X se selecciona del grupo que consiste en of -S-, -O-, -S(O)2-, S(O)-, -(C(R3)2)m- y -N(R3)-; T está ausente o presente y, si está presente se selecciona del grupo que consiste en alquilo; arilo y heteroarilo, en donde cuando cada uno de dichos T arilo y heteroarilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden opcionalmente tomarse junto con los átomos de carbono a los cuales están unidos para formar un anillo arilo o heteroarilo de cinco a ocho miembros, en donde cada uno de los antes mencionados T arilo y heteroarilo, opcionalmente con dicho arilo o heteroarilo de cinco a ocho miembros está independientemente no substitutido o substituido con uno a cuatro restos R10 que pueden ser iguales o diferentes; U está ausente o presente y, si está presente se selecciona del grupo que consiste en -O-, -O-C(O)NH-, -OC(O)N(alquilo)-, -C(O)-, -C(O)O-, -C(O)NH-, -C(O)N(alquilo)-, -C(=N-OH)-alquilo-, y -C(=N-O-alquil)-alquilo-; V está ausente o presente y, si está presente, V se selecciona del grupo que consiste en alquilo, alquinilo, cicloalquilo, heterociclilo, arilo, heteroarilo y N-oxidos de dicho heterociclilo y heteroarilo, en donde cuando cada uno de dichos V cicloalquilo, heterociclilo, arilo, heteroarilo y N-oxidos de dicho heterociclilo y heteroarilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden estar opcionalmente tomados conjuntamente con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros, donde cada uno de dichos V alquilo, alquinilo, cicloalquilo, heterociclilo, arilo, heteroarilo y heterociclilo, opcionalmente con dichos cicloalquilo, arilo, heterociclilo, o heteroarilo de cinco a ocho miembros independientemente no substitutido o substituido con uno a cuatro restos R10 que pueden ser iguales o diferentes; Y se selecciona del grupo que consiste en una union covalente, -(C(R4)2)n-, -N(R4)-, -C(O)N(R4)-, -N(R4)C(O)-, -N(R4)C(O)N(R4)-, -S(O)2N(R4)-, -N(R4)-S(O)2-, -O-, -S-, -C(O)-, -S(O)-, y -S(O)2-; Z se selecciona del grupo que consiste en una union covalente, -(C(R4)2)n-, -N(R4)-, -C(O)N(R4)-, -N(R4)C(O)-, -N(R4)C(O)N(R4)-, -S(O)2N(R4)-, -N(R4)-S(O)2-, -O-, -S- , -C(O)-, -S(O)-, y -S(O)2-; m es 1 a 3: n es 1 a 3; R1 está seleccionado del grupo que consiste en H, ciano, -C(O)OH, -C(O)O-alquilo, -C(O)NH2, -C(O)NH(alquilo), -C(O)N(alquilo)2, -alquinilo, halogeno, alquilo, cicloalquilo, haloalquilo, arilo, heteroarilo, y heterociclilo, en donde cuando cada uno de dichos cicloalquilo, heterociclilo, arilo y heteroarilo contienen dos radicales en átomos de carbono adyacentes, dichos radicales pueden estar opcionalmente tomados conjuntamente con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros; donde cada uno de los R1 alquilo, alquinilo, arilo, heteroarilo, y heterociclilo, opcionalmente con el anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco o seis miembros no substitutido o en forma opcional está substituido independientemente con uno a cuatro restos R20 los cuales pueden ser iguales o diferentes; con la salvedad de que cuando Y es -N(R4)-, -S- o -O-, entonces R1 no es halogeno o ciano; R2 se selecciona del grupo que consiste en H, ciano, -C(O)OH, -C(O)O-alquilo, -C(O)NH2, -C(O)NH(alquilo), -C(O)N(alquilo)2, alquinilo, halogeno, alquilo, cicloalquilo, haloalquilo, arilo, heteroarilo, y heterociclilo, donde cuando cada uno de dichos cicloalquilo, heterociclilo, arilo y heteroarilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden opcionalmente tomarse junto con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros; en donde cada uno de los R2 alquilo, cicloalquilo, arilo, heteroarilo, y heterociclilo, en forma opcional con el anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a seis miembros no substitutido o en forma opcional está substituido independientemente con uno a cuatro restos R20 que pueden ser iguales o diferentes; con la salvedad de que cuando Y es -N(R4)-, -S- o -O-, entonces R2 no es halogeno o ciano; cada R3 es igual o diferente y seleccionado en forma independiente del grupo que consiste en H, alquilo, y arilo; cada R4 es igual o diferente y seleccionado en forma independiente del grupo que consiste en H, alquilo, cicloalquilo, haloalquilo, hidroxi, -alquilcicloalquilo, -alquil-N(alquil)2, heterociclilo, arilo, y heteroarilo en donde cuando cada uno de dichos cicloalquilo, heterociclilo, arilo, y heteroarilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden opcionalmente tomarse junto con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros; R10 se selecciona del grupo que consiste en hidrogeno, ciano, nitro, -C(R4)=N-OR4, -OR4, -SR4, -N(R4)2, -S(O)R4, -S(O)2R4, -N(R4)S(O)2R4, -N(R4)-C(O)-R4, -N(R4)-C(O)-N(R4)2, -N(R4)-C(O)-OR4, -OC(O)N(R4)2, -C(O)N(R4)-S(O)2R4, -S(O)2N(R4)-C(O)-R4, - C(O)N(R4)C(O)R4, -C(O)N(R4)C(O)NR4, -S(O)2N(R4)2, -N(R4)-C(=NR4)-N(R4)2, -N(R4)-C(=N-CN)-N(R4)2, -haloalcoxi, -C(O)OR4, -C(O)R4, -C(O)N(R4)2, halogeno, alquilo, haloalquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo, donde cada uno alquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo, en donde cada uno de los R10 alquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo no está substitutido o en forma opcional está substituido independientemente con uno a cuatro restos R30 que pueden ser iguales o diferentes; o donde dos restos R10, cuando están unidos al mismo átomo de carbono o átomos de carbono adyacentes pueden en forma opcional tomarse junto con el/los átomo(s) de carbono a los cuales están unidos para formar un anillo cicloalquilo, cicloalquenilo, heterociclilo, arilo, o heteroarilo; R20 se selecciona del grupo que consiste en of ciano, nitro, -C(R4)=N-OR4, -OR4, -SR4, -N(R4)2, -S(O)R4, -S(O)2R4, -N(R4)S(O)2R4, -N(R4)-C(O)-R4, -N(R4)-C(O)-N(R4)2, -N(R4)- C(O)-OR4, -OC(O)N(R4)2, -C(O)N(R4)-S(O)2R4, -S(O)2N(R4)-C(O)-R4, -C(O)N(R4)C(O)R4, -C(O)N(R4)C(O)NR4, -S(O)2N(R4)2, -N(R4)-C(=NR4)-N(R4)2, -N(R4)-C(=N-CN)-N(R4)2, -haloalcoxi, -C(O)OR4, -C(O)R4, -C(O)N(R4)2, halogeno, alquilo, haloalquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo; en donde cuando cada uno de dichos R20 arilo, heteroarilo, heterociclilo y cicloalquilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden opcionalmente tomarse junto con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros; en donde cada uno dichos R20 alquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo, en forma opcional con dicho anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros no substitutido o está substituido con uno a cuatro restos seleccionados independientemente del grupo que consiste en alquilo, halo, haloalquilo, hidroxi, alcoxi, haloalcoxi, hidroxialquilo, ciano, nitro, -NH2, -NH(alquil), y -N(alquil)2; o cuando dos restos R20 cuando están unidos al mismo átomo de carbono o átomos de carbono adyacentes pueden tomarse opcionalmente en forma conjunta con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, cicloalquenilo, heterociclilo, arilo, o heteroarilo; R30 se selecciona del grupo que consiste en of ciano, nitro, -C(R4)=N-OR4, -OR4, -SR4, -N(R4)2, -S(O)R4, -S(O)2R4, - N(R4)S(O)2R4, -N(R4)-C(O)-R4, -N(R4)-C(O)-N(R4)2, -N(R4)-C(O)-OR4, -OC(O)N(R4)2, -C(O)N(R4)-S(O)2R4, -S(O)2N(R4)-C(O)-R4, -C(O)N(R4)C(O)R4, -C(O)N(R4)C(O)NR4, -S(O)2N(R4)2, -N(R4)-C(=NR4)-N(R4)2, -N(R4)-C(=N-CN)-N(R4)2, -haloalcoxi, -C(O)OR4, - C(O)R4, -C(O)N(R4)2, halogeno, alquilo, haloalquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo; en donde cuando cada uno de dichos R30 arilo, heteroarilo, heterociclilo y cicloalquilo contiene dos radicales en átomos de carbono adyacentes, dichos radicales pueden opcionalmente tomarse junto con los átomos de carbono a los cuales están unidos para formar un anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros; en donde cada uno dichos R30 alquilo, arilo, heteroarilo, heterociclilo, y cicloalquilo, en forma opcional con dicho anillo cicloalquilo, arilo, heterociclilo o heteroarilo de cinco a ocho miembros no está substitutido o está substituido con uno a cuatro restos seleccionados independientemente del grupo que consiste en alquilo, halo, haloalquilo, hidroxi, alcoxi, haloalcoxi, ciano, nitro, -NH2, -NH(alquilo), y -N(alquilo)2; o cuando dos restos R30 cuando están unidos al mismo átomo de carbono o átomos de carbono adyacentes pueden en forma opcional tomarse junto con el/los átomo(s) de carbono a los cuales están unidos para formar un anillo cicloalquilo, cicloalquenilo, heterociclilo, arilo, o heteroarilo; con la salvedad de que al menos uno de T, U, y V debe estar presente; y además que se hayan cumplido al menos una de las condiciones (a) - (e): (a) al menos uno de T y V está presente, y V es diferente de alquinilo; en donde dicho T o V está substituido con al menos un resto R10 seleccionado del grupo que consiste en ciano, - C(O)OR4, -C(O)R4, -C(O)N(R4)2, -C(O)N(R4)C(O)R4, -C(O)N(R4)C(O)NR4, -SR4, -S(O)2R4, -N(R4)-C(O)OR4, -OC(O)N(R4)2, -N(R4)C(O)N(R
ARP070100164A 2006-01-17 2007-01-15 Compuestos para el tratamiento de trastornos inflamatorios AR059037A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75930006P 2006-01-17 2006-01-17

Publications (1)

Publication Number Publication Date
AR059037A1 true AR059037A1 (es) 2008-03-12

Family

ID=38038495

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070100163A AR059036A1 (es) 2006-01-17 2007-01-15 Compuestos para el tratamiento de trastornos inflamatorios
ARP070100164A AR059037A1 (es) 2006-01-17 2007-01-15 Compuestos para el tratamiento de trastornos inflamatorios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070100163A AR059036A1 (es) 2006-01-17 2007-01-15 Compuestos para el tratamiento de trastornos inflamatorios

Country Status (17)

Country Link
US (4) US7524842B2 (es)
EP (2) EP1973901B1 (es)
JP (2) JP2009523797A (es)
KR (2) KR20080085222A (es)
CN (2) CN101410390A (es)
AR (2) AR059036A1 (es)
AU (2) AU2007207711A1 (es)
BR (2) BRPI0706598A2 (es)
CA (2) CA2637196A1 (es)
EC (2) ECSP088626A (es)
IL (2) IL192691A0 (es)
NO (2) NO20083567L (es)
PE (2) PE20071241A1 (es)
RU (2) RU2008133383A (es)
TW (2) TW200736247A (es)
WO (2) WO2007084455A1 (es)
ZA (1) ZA200806072B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005275213A1 (en) 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
ZA200707125B (en) 2005-01-25 2008-11-26 Synta Pharmaceuticals Corp Compounds for inflammation and immune-related uses
US7902352B2 (en) 2005-05-06 2011-03-08 Medtronic, Inc. Isolated nucleic acid duplex for reducing huntington gene expression
MX2008002073A (es) * 2005-08-12 2008-04-16 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios.
AR059036A1 (es) * 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US20090175852A1 (en) 2006-06-06 2009-07-09 Schering Corporation Imidazopyrazines as protein kinase inhibitors
US7998961B2 (en) 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents
CN101186611B (zh) 2006-11-15 2011-05-18 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉-2-酮衍生物及其制备和应用
CN101186612B (zh) * 2006-11-15 2012-10-03 天津和美生物技术有限公司 可抑制细胞释放肿瘤坏死因子的吡咯啉衍生物及其制备和应用
TW201024304A (en) 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
TW201024303A (en) 2008-09-24 2010-07-01 Schering Corp Compounds for the treatment of inflammatory disorders
US8541572B2 (en) 2008-11-10 2013-09-24 Merck Sharp & Dohme Corp. Compounds for the treatment of inflammatory disorders
EP2355825A2 (en) 2008-11-10 2011-08-17 Schering Corporation Compounds for the treatment of inflammatory disorders
HUE030114T2 (en) 2010-07-08 2017-04-28 Kaken Pharma Co Ltd N-hydroxyformamide derivatives and pharmaceutical compositions containing them
EP2705024B1 (en) * 2011-05-03 2015-12-16 Merck Sharp & Dohme Corp. Alkyne benzotriazole derivatives
WO2013085016A1 (ja) 2011-12-09 2013-06-13 科研製薬株式会社 ピリドン誘導体およびそれを含有する医薬
AR092971A1 (es) * 2012-10-26 2015-05-06 Lilly Co Eli Inhibidores de agrecanasa
TWI636782B (zh) 2013-06-07 2018-10-01 科研製藥股份有限公司 （＋）－５－（３,４－二氟苯基）－５－［（３－甲基－２－氧代吡啶－１（２ｈ）－基）甲基］咪唑啶－２,４－二酮及含有此之醫藥
CN104803861B (zh) * 2014-01-27 2017-05-24 上海博邦医药科技有限公司 一种合成盐酸他喷他多的方法
SG11201606080SA (en) 2014-02-03 2016-08-30 Vitae Pharmaceuticals Inc Dihydropyrrolopyridine inhibitors of ror-gamma
CN107074852B (zh) 2014-10-14 2019-08-16 生命医药有限责任公司 ROR-γ的二氢吡咯并吡啶抑制剂
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
AU2016215432B2 (en) 2015-02-02 2020-07-30 Valo Early Discovery, Inc. 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
AU2016289079B2 (en) * 2015-07-09 2020-10-22 Mitsubishi Tanabe Pharma Corporation Novel imide derivatives and use thereof as medicine
CN105153048B (zh) * 2015-07-31 2017-10-24 苏州大学 一种2,4‑喹唑啉二酮类化合物的制备方法
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
EP3377482B1 (en) 2015-11-20 2021-05-12 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
TWI757266B (zh) 2016-01-29 2022-03-11 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
KR20190020343A (ko) 2016-06-29 2019-02-28 오리온 코포레이션 벤조디옥산 유도체 및 이의 약제학적 용도
SMT202100723T1 (it) * 2016-07-20 2022-01-10 Novartis Ag Derivati di amminopiridina e loro uso come inibitori selettivi di alk-2
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
CN107382679A (zh) * 2017-07-12 2017-11-24 安徽省诚联医药科技有限公司 达格列净中间体的制备方法
CN107311962A (zh) * 2017-07-12 2017-11-03 安徽省诚联医药科技有限公司 依帕列净中间体的制备方法
MA49685A (fr) 2017-07-24 2021-04-14 Vitae Pharmaceuticals Llc INHIBITEURS DE ROR gamma
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
CN107573311A (zh) * 2017-08-09 2018-01-12 江苏工程职业技术学院 一种达格列净的合成方法
CN107556309B (zh) * 2017-09-11 2020-12-01 浙江永宁药业股份有限公司 多取代四氢萘啶类化合物的药物用途及其制备方法
JP7349456B2 (ja) 2018-07-03 2023-09-22 ジエンス ヘンルイ メデイシンカンパニー リミテッド ピリドピリミジン誘導体、その調製方法およびその医学的使用
WO2021021979A2 (en) 2019-07-30 2021-02-04 Eikonizo Therapapeutics, Inc. Hdac6 inhibitors and uses thereof
PE20230251A1 (es) 2019-11-22 2023-02-07 Incyte Corp Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
WO2021204185A1 (zh) * 2020-04-10 2021-10-14 深圳信立泰药业股份有限公司 一种苯并[d]氮杂卓类衍生物蛋白聚糖酶2抑制剂及其制备方法和医药用途
CN113754635B (zh) * 2020-06-02 2024-06-21 成都康弘药业集团股份有限公司 稠环类化合物及其制备方法和用途
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
US20240124443A1 (en) * 2021-02-05 2024-04-18 Scinnohub Pharmaceutical Co., Ltd Plasmin inhibitor, preparation method therefor, and application thereof
WO2025038927A1 (en) * 2023-08-16 2025-02-20 Raythera, Inc. Modulators of tnf alpha activity and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6228869B1 (en) * 1996-10-16 2001-05-08 American Cyanamid Company Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
JP2003507362A (ja) * 1999-08-18 2003-02-25 ワーナー−ランバート・カンパニー マトリックスメタロプロテイナーゼ阻害剤として有用なヒドロキサム酸化合物
HK1049334B (en) * 2000-03-17 2004-07-16 Bristol-Myers Squibb Pharma Company Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SK10932003A3 (sk) 2001-03-15 2004-04-06 Astrazeneca Ab Metaloproteinázové inhibítory
WO2002096426A1 (en) 2001-05-25 2002-12-05 Bristol-Myers Squibb Company Hydantion derivatives as inhibitors of matrix metalloproteinases
US6936620B2 (en) 2001-12-20 2005-08-30 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
US7294624B2 (en) 2001-12-20 2007-11-13 Bristol Myers Squibb Company Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
GB0221246D0 (en) * 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
EP1546109A4 (en) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
AU2003297364B2 (en) 2002-12-19 2009-07-09 Vertex Pharmaceuticals Incorporated Inhibitors of TACE
US7504424B2 (en) * 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7488745B2 (en) * 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
AU2005275213A1 (en) * 2004-07-16 2006-02-23 Schering Corporation Hydantoin derivatives for the treatment of inflammatory disorders
AR059036A1 (es) 2006-01-17 2008-03-12 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US7998961B2 (en) * 2006-08-31 2011-08-16 Schering Corporation Hydantoin derivatives useful as antibacterial agents

Also Published As

Publication number Publication date
JP2009523797A (ja) 2009-06-25
AU2007207707A1 (en) 2007-07-26
ECSP088625A (es) 2008-08-29
EP1973901B1 (en) 2014-12-17
US7683088B2 (en) 2010-03-23
KR20080085222A (ko) 2008-09-23
CN101405286A (zh) 2009-04-08
IL192690A0 (en) 2009-02-11
NO20083568L (no) 2008-10-16
AR059036A1 (es) 2008-03-12
US7524842B2 (en) 2009-04-28
RU2008133383A (ru) 2010-02-27
WO2007084451A1 (en) 2007-07-26
PE20071240A1 (es) 2008-01-14
TW200736247A (en) 2007-10-01
US20090156586A1 (en) 2009-06-18
CN101410390A (zh) 2009-04-15
EP1973901A1 (en) 2008-10-01
KR20080085221A (ko) 2008-09-23
ZA200806072B (en) 2009-04-29
WO2007084455A1 (en) 2007-07-26
EP1973900B1 (en) 2017-04-05
US20100120838A1 (en) 2010-05-13
CA2637196A1 (en) 2007-07-26
TW200738688A (en) 2007-10-16
CA2637198A1 (en) 2007-07-26
AU2007207711A1 (en) 2007-07-26
PE20071241A1 (es) 2008-01-14
IL192691A0 (en) 2009-02-11
JP2009523796A (ja) 2009-06-25
US20070197564A1 (en) 2007-08-23
BRPI0706599A2 (pt) 2011-03-29
NO20083567L (no) 2008-10-16
US7772263B2 (en) 2010-08-10
RU2008133382A (ru) 2010-02-27
EP1973900A1 (en) 2008-10-01
US20070265299A1 (en) 2007-11-15
US8178553B2 (en) 2012-05-15
BRPI0706598A2 (pt) 2011-04-05
ECSP088626A (es) 2008-08-29

Similar Documents

Publication Publication Date Title
AR059037A1 (es) Compuestos para el tratamiento de trastornos inflamatorios
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
CO5631436A2 (es) Amidas y acidos derivados del bencimidazol para el tratamiento del dolor y la inflamacion
AR060768A1 (es) Compuestos de imidazol sustituidos inhibidores del factor x, composiciones farmaceuticas que los contienen y usos como agentes antitromboticos.
AR069334A1 (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana
AR059197A1 (es) Derivados de indazolo piridina para el tratamiento de hiv
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
AR081848A1 (es) Inhibidores de la proteina ns5a del vhc
AR072751A1 (es) Compuestos heterociclicos inhibidores de la proliferacion celular
AR053436A1 (es) Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas
AR068075A1 (es) Compuestos de piperazina con accion herbicida. proceso de preparacion
AR072224A1 (es) Derivados de pirimidona sustituidos
AR046046A1 (es) Imidazoquinolinas alcoxi sustituidas. composiciones farmaceuticas.
AR072913A1 (es) Naftiridinas sustituidas y su utilizacion como medicamento
AR077328A1 (es) Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos
AR077060A1 (es) Compuestos antivirales
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
ES2485040T3 (es) Inhibidores de cinasa de adhesión focal
AR044402A1 (es) Compuestos heterociclicos y su uso como inmunodepresores. composiciones farmaceuticas que los contienen.
BRPI0720993B8 (pt) usos de compostos análogos de ciclopamina
AR054621A1 (es) 1-aril-4-ciclopropilpirazoles sustituidos
AR080596A1 (es) Compuestos alquilamido y composiciones farmaceuticas
AR073501A1 (es) Derivados de pirimido[5,4-d]pirimidina inhibidores de la tirosinoquinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal